Y-mAbs Therapeutics Inc. (YMAB)
NASDAQ: YMAB
· Real-Time Price · USD
8.61
0.02 (0.23%)
At close: Sep 15, 2025, 3:59 PM
0.23% (1D)
| Bid | 8.59 |
| Market Cap | 391.22M |
| Revenue (ttm) | 85.39M |
| Net Income (ttm) | -22.22M |
| EPS (ttm) | -0.5 |
| PE Ratio (ttm) | -17.22 |
| Forward PE | -9.78 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 8.67 |
| Volume | 760,675 |
| Avg. Volume (20D) | 905,066 |
| Open | 8.61 |
| Previous Close | 8.59 |
| Day's Range | 8.61 - 8.61 |
| 52-Week Range | 3.55 - 16.11 |
| Beta | 0.53 |
| Ex-Dividend Date | n/a |
About YMAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol YMAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for YMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsY-mAbs Therapeutics Inc. is scheduled to release its earnings on
Nov 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+103.34%
Y-MAbs Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
9 months ago
-0.77%
Y-MAbs Therapeutics shares are trading higher after Brookline Capital initiated coverage on the stock with a Buy rating and announced a price target of $17.
1 month ago · https://thefly.com
Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan StanleyMorgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of $8.60, up from $7, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per sha...
1 month ago · https://thefly.com
Y-mAbs Therapeutics downgraded to Perform from Outperform at OppenheimerOppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics without a price target to Perform from Outperform after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in c...
